Bispecific antibodies specific for PD1 and TIM3

Patent metadata

Field	Value
Publication number	US-11130810-B2
Application number	US-201916367017-A
Country	US
Kind code	B2
Filing date	Mar 27, 2019
Priority date	Oct 2, 2015
Publication date	Sep 28, 2021
Grant date	Sep 28, 2021

Abstract

The invention relates to bispecific antibodies comprising a first antigen-binding site that specifically binds to PD1 and a second antigen-binding site that specifically binds to TIM3, in particular to bispecific antibodies, wherein the bispecific antibody binds to 5 TIM3 with a lower binding affinity when compared to the binding to PD1. The invention further relates to methods of producing these molecules and to methods of using the same.

First claim

What is claimed is:

1. A method of treating a disease in an individual, the method comprising administering a therapeutically effective amount of a bispecific antibody comprising a first antigen-binding site that specifically binds to PD1 and a second antigen-binding site that specifically binds to TIM3, wherein
said first antigen-binding site specifically binding to PD1 comprises
a VH domain comprising
(i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:37,
(ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:38, and
(iii) HVR-H3 comprising an amino acid sequence of SEQ ID NO:39; and
a VL domain comprising
(i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:40;
(ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:41, and
(iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:42; and

said second antigen-binding site specifically binding to TIM3 comprises
(a) a VH domain comprising
(i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:1,
(ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:2, and
(iii) HVR-H3 comprising an amino acid sequence of SEQ ID NO:3; and
a VL domain comprising
(i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:4 or SEQ ID NO:11 or SEQ ID NO:12,
(ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:5, and
(iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:6; or

(b) a VH domain comprising
(i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:17,
(ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:18, and
(iii) HVR-H3 comprising an amino acid sequence of SEQ ID NO:19; and
a VL domain comprising
(i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:20,
(ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:21, and
(iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:22; or

(c) a VH domain comprising
(i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:29,
(ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:30, and
(iii) HVR-H3 comprising an amino acid sequence of SEQ ID NO:31; and
a VL domain comprising
(i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:32,
(ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:33, and
(iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:34.

2. The method of claim 1 , wherein the bispecific antibody binds to TIM3 with an at least 50-fold lower binding affinity when compared to the binding to PD1.

3. The method according to claim 1 , wherein
said first antigen-binding site specifically binding to PD1 comprises
(a) a VH domain comprising the amino acid sequence of SEQ ID NO: 43 and a VL domain comprising the amino acid sequence of SEQ ID NO: 44, or
(b) a VH domain comprising the amino acid sequence of SEQ ID NO: 45 and a VL domain comprising the amino acid sequence of SEQ ID NO: 46, or
(c) a VH domain comprising the amino acid sequence of SEQ ID NO: 45 and a VL domain comprising the amino acid sequence of SEQ ID NO: 47, or
(d) a VH domain comprising the amino acid sequence of SEQ ID NO: 45 and a VL domain comprising the amino acid sequence of SEQ ID NO: 48, or
(e) a VH domain comprising the amino acid sequence of SEQ ID NO: 45 and a VL domain comprising the amino acid sequence of SEQ ID NO: 49,

and said second antigen-binding site specifically binding to TIM3 comprises
(a) a VH domain comprising the amino acid sequence of SEQ ID NO: 7 and a VL domain comprising the amino acid sequence of SEQ ID NO: 8, or
(b) a VH domain comprising the amino acid sequence of SEQ ID NO: 9 and a VL domain comprising the amino acid sequence of SEQ ID NO: 10, or
(c) a VH domain comprising the amino acid sequence of SEQ ID NO: 13 and a VL domain comprising the amino acid sequence of SEQ ID NO: 14, or
(d) a VH domain comprising the amino acid sequence of SEQ ID NO: 15 and a VL domain comprising the amino acid sequence of SEQ ID NO: 16, or
(e) a VH domain comprising the amino acid sequence of SEQ ID NO: 23 and a VL domain comprising the amino acid sequence of SEQ ID NO: 24, or
(f) a VH domain comprising the amino acid sequence of SEQ ID NO: 25 and a VL domain comprising the amino acid sequence of SEQ ID NO: 26, or
(g) a VH domain comprising the amino acid sequence of SEQ ID NO: 27 and a VL domain comprising the amino acid sequence of SEQ ID NO: 28, or
(h) a VH domain comprising the amino acid sequence of SEQ ID NO: 35 and a VL domain comprising the amino acid sequence of SEQ ID NO: 36.

4. The method according to claim 1 , wherein
said first antigen-binding site specifically binding to PD1 comprises a VH domain comprising the amino acid sequence of SEQ ID NO: 45 and a VL domain comprising the amino acid sequence of SEQ ID NO: 46,
and said second antigen-binding site specifically binding to TIM3 comprises a VH domain comprising the amino acid sequence of SEQ ID NO: 15 and a VL domain comprising the amino acid sequence of SEQ ID NO: 16 or a VH domain comprising the amino acid sequence of SEQ ID NO: 25 and a VL domain comprising the amino acid sequence of SEQ ID NO: 26.

5. The method according to claim 1 , wherein
said first antigen-binding site specifically binding to PD1 comprises a VH domain comprising the amino acid sequence of SEQ ID NO: 45 and a VL domain comprising the amino acid sequence of SEQ ID NO: 46, and
said second antigen-binding site specifically binding to TIM3 comprises a VH domain comprising the amino acid sequence of SEQ ID NO: 25 and a VL domain comprising the amino acid sequence of SEQ ID NO: 26.

6. The method according to claim 1 , wherein the bispecific antibody is a human, humanized or chimeric antibody.

7. The method of claim 1 , wherein the bispecific antibody comprises an Fc domain, a first Fab fragment comprising the antigen-binding site that specifically binds to PD1 and a second Fab fragment comprising the antigen-binding site that specifically binds to TIM3.

8. The method of claim 7 , wherein the Fc domain is an IgG1 Fc domain or an IgG4 Fc domain.

9. The method of claim 7 , wherein the Fc domain comprises one or more amino acid substitution that reduces binding to an Fc receptor, in particular towards Fcγ receptor.

10. The method of claim 7 , wherein the Fc domain is of human IgG1 subclass with the amino acid mutations L234A, L235A and P329G (numbering according to Kabat EU index).

11. The method of claim 7 , wherein the Fc domain comprises a modification promoting the association of the first and second subunit of the Fc domain.

12. The method of claim 7 , wherein a first subunit of the Fc domain comprises knobs and a second subunit of the Fc domain comprises holes according to the knobs into holes method.

13. The method of claim 7 , wherein the first subunit of the Fc domain comprises the amino acid substitutions S354C and T366W (EU numbering) and the second subunit of the Fc domain comprises the amino acid substitutions Y349C, T366S and Y407V (numbering according to Kabat EU index).

14. The method of claim 7 , wherein in one of the Fab fragments the variable domains VL and VH are replaced by each other so that the VH domain is part of the light chain and the VL domain is part of the heavy chain.

15. The method of claim 14 , wherein in the first Fab fragment comprising the antigen-binding site that specifically binds to PD1 the variable domains VL and VH are replaced by each other.

16. The method of claim 7 , wherein in one of the Fab fragments in the constant domain CL the amino acid at position 124 is substituted independently by lysine (K), arginine (R) or histidine (H) (numbering according to Kabat EU Index), and in t

Assignees

• Hoffmann La Roche

Inventors

• Codarri-Deak Laura
• Fertig Georg
• Fischer Jens
• Klein Christian
• Levitski Viktor
• Lifke Valeria
• Perro Mario
• Regula Joerg Thomas
• Schlothauer Tilman
• Seeber Stefan
• Umana Pablo
• Wuensche Ildiko
• Zwick Adrian

Classifications

• C12N2800/107

  for mammalian · CPC title

• C12N2510/00

  Genetically modified cells · CPC title

• C12N15/85

  for animal cells · CPC title

• C12N5/0686

  Kidney cells · CPC title

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title